

**Anti MDA-treated low-density lipoprotein (human, LDL)
Mouse monoclonal antibody**

PRODUCT NO.

HYB 262-05

Subclass: IgG_{2b}/I

Clone: 10G10

PRESENTATION

Preparation: Protein-A/G purified

Content: Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.

Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide

Storage: 4-8°C without exposure to light. No precautions necessary during handling.

ANTIGEN

Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood. LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearance of cholesterol from the circulation. In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36. Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described. MDA-treated LDL appear to be different from LDL oxidized by other means.

IMMUNOGEN

Low-density lipoprotein purified from human plasma and treated with malonyldialdehyde (MDA) and adsorbed onto aluminum hydroxide gel

SPECIFICITY

HYB 262-05 reacts with MDA-treated LDL but not with native LDL

EPI TOPE SPECIFICITY

Not determined

REACTIVITY

HYB 262-05 reacts with MDA-treated LDL in ELISA and in SDS-PAGE immunoblotting

CULTURE MEDIUM

RPMI 1640 with 10% fetal calf serum

FUSION PARTNER

X63-Ag8.653

IMMUNIZATION

Female CF1 x BALB/c mice immunized by intraperitoneal injection

APPLICATION

Method	Usability	References
ELISA	Yes	
Immunoblotting	Yes	
Immunohistochemistry	Not determined	

REFERENCES

1. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL (1990) Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. *Arteriosclerosis* 10:325-335.
2. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. *Lancet* 341:923-925.
3. Binder JC, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between *Streptococcus pneumoniae* and oxidized LDL. *Nat Med* 9:736-743.

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.